This content is machine translated Dyslipidemia: "Treat-to-target" Risk-adapted individual LDL-C targets Together with arterial hypertension and diabetes mellitus, lipid metabolism disorders are among the most important modifiable cardiovascular risk factors. In addition to statins, various modern substance classes are now available...…
View Post 4 min This content is machine translated CV Health Update 2023 Hypercholesterolemia – Strengthen Cardiovascular Prevention At the hybrid event “CV Health Update 2023,” Prof. Isabella Sudano, MD, Senior Physician, Head of Cardiovascular Risk Factors, Department of Cardiology Heart Center University Hospital Zurich, presented the current…
View Post 5 min This content is machine translated Swiss Society of Cardiology Joint Annual Meeting 2018, Basel Advances in atherosclerosis therapy The PCSK9 inhibitors evolocumab and alirocumab can be used successfully to lower LDL cholesterol, as shown by large outcome studies. Whether anti-inflammation can also prophylactically reduce cardiovascular risk has been…
View Post 7 min This content is machine translated ACC 2018 Success story of PCSK9 inhibition continues For the first time after the highly acclaimed FOURIER trial, a PCSK9 inhibitor now also shows a mortality benefit in secondary prevention. The product in question is alirocumab. Experts are…
